PBYI•benzinga•
Puma Biotechnology's NERLYNX Added To NCCN Guidelines For HER2-Mutated Cervical Cancer; Approved As Second-Line Therapy For Recurrent Or Metastatic Disease Based On Phase II SUMMIT Trial Results
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 23, 2024 by benzinga